Celine Pisibon
Nice, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.
Journal: Cell death and differentiation
Published: November 13, 2025
SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target.
Journal: Cell death & disease
Published: April 28, 2025
Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.
Journal: EMBO molecular medicine
Published: August 20, 2024
Loss of LYN Is Frequent in Targeted Therapy-Resistant Melanoma Cells and Favors Metastatic Properties.
Journal: The Journal of investigative dermatology
Published: April 01, 2024
When ubiquitination intertwines with cutaneous melanoma: a mechanism to explore
Journal: Medecine sciences : M/S
Published: March 23, 2024
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.
Journal: EMBO molecular medicine
Published: March 17, 2023
Immune Checkpoints in Cancers: From Signaling to the Clinic.
Journal: Cancers
Published: August 13, 2021
An Update on the Role of Ubiquitination in Melanoma Development and Therapies.
Journal: Journal of clinical medicine
Published: January 08, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026